Anaphylaxis News and Research RSS Feed - Anaphylaxis News and Research

Anaphylaxis is an acute multi-system severe type I hypersensitivity reaction. Due in part to the variety of definitions, between 1% and 15% of the population of the United States can be considered "at risk" for having an anaphylactic reaction if they are exposed to one or more allergens. Of those people who actually experience anaphylaxis, up to 1% may die as a result.
Leading nonprofit patient education organization offers allergy-related restaurant safety tips

Leading nonprofit patient education organization offers allergy-related restaurant safety tips

Eating out is an American pastime - but for the millions of Americans with food or latex allergies, navigating the maze of restaurant and menu options can prove challenging, especially during the hustle and bustle of the holidays. [More]
Experts characterize racial and ethnic differences in food allergies among U.S. children

Experts characterize racial and ethnic differences in food allergies among U.S. children

Allergy and immunology experts at Rush University Medical Center, Cincinnati Children's Hospital Medical Center and Ann & Robert H. Lurie Children's Hospital of Chicago have conducted the first study designed to assess and characterize the racial and ethnic difference in food allergies among children in the U.S. [More]
New technique shows promise for therapeutic reversal of food allergies

New technique shows promise for therapeutic reversal of food allergies

"This discovery reverses food allergies in mice, and we have many people with allergies volunteering their own cells for us to use in lab testing to move this research forward," said professor John Gordon, lead scientist behind the discovery just published in the current issue of the Journal of Allergy and Clinical Immunology. [More]
Researchers discover new therapeutic target for controlling fatal allergic reactions

Researchers discover new therapeutic target for controlling fatal allergic reactions

Researchers in France have identified a molecular motor that controls the release of inflammatory factors that cause severe and fatal allergic reactions. [More]
New bio-photonic device aims to take drug hypersensitivity detection into new era

New bio-photonic device aims to take drug hypersensitivity detection into new era

Over 2.5 million people in Europe and more than 5.4 million Americans suffer from hypersensitivity to Beta Lactam Antibiotics (BLCs), the most commonly prescribed drugs that contain the penicillin family, with up to 10 percent of people reporting an allergy. [More]
FAAM 2016: Experts discuss advancements in diagnosis, management of food allergies and anaphylaxis

FAAM 2016: Experts discuss advancements in diagnosis, management of food allergies and anaphylaxis

The European Academy of Allergy and Clinical Immunology has announced today the inauguration of its 4th Food Allergy and Anaphylaxis Meeting (FAAM), hosting over 1,200 international researchers, clinicians and allied health professionals in Rome from 13–15 October 2016. [More]
Penicillin allergy testing: an interview with Dr. Eric Macy

Penicillin allergy testing: an interview with Dr. Eric Macy

Penicillin was one of the first antibiotics developed and has saved millions of lives. First used in the early 1940s, penicillin is still one of the most widely used and least toxic family of antibiotics. [More]
Study finds oral immunotherapy safe, effective at suppressing peanut allergy in preschool children

Study finds oral immunotherapy safe, effective at suppressing peanut allergy in preschool children

Nearly 80 percent of peanut-allergic preschool children successfully incorporated peanut-containing foods into their diets after receiving peanut oral immunotherapy (OIT), a clinical trial has found. [More]
FDA approves new injection to improve blood sugar levels in adults with type 2 diabetes

FDA approves new injection to improve blood sugar levels in adults with type 2 diabetes

The U.S. Food and Drug Administration approved Adlyxin (lixisenatide), a once-daily injection to improve glycemic control (blood sugar levels), along with diet and exercise, in adults with type 2 diabetes. [More]
Researchers aim to improve medical treatment for people with insect venom allergy

Researchers aim to improve medical treatment for people with insect venom allergy

A team of researchers has elucidated individual profiles of allergy reactivity in patients that are not protected after treatment with immunotherapy. The aim is to improve medical treatment of people who are allergic to insect stings. [More]
Zinbryta gets FDA approval for treating adults with relapsing forms of MS

Zinbryta gets FDA approval for treating adults with relapsing forms of MS

The U.S. Food and Drug Administration today approved Zinbryta (daclizumab) for the treatment of adults with relapsing forms of multiple sclerosis (MS). Zinbryta is a long-acting injection that is self- administered by the patient monthly. [More]
Food-triggered atopic dermatitis in children may lead to life-threatening anaphylaxis risk

Food-triggered atopic dermatitis in children may lead to life-threatening anaphylaxis risk

Elimination of the food that triggers atopic dermatitis, or eczema, is associated with increased risk of developing immediate reactions to that food, according to the results of a large-scale study recently published in the Journal of Allergy and Clinical Immunology. [More]
Common misconception about penicillin allergies

Common misconception about penicillin allergies

It's time for your primary care check-up, and the doctor asks you to list any known drug allergies. "Penicillin," you say immediately, although you can't remember actually taking the drug or having a reaction to it—it was your parents who said so. According to a Texas A&M Health Science Center allergist, many people who believe they're allergic to this antibiotic may not actually be allergic at all. [More]
New study finds no increase in food-specific IgE levels linked to food allergies

New study finds no increase in food-specific IgE levels linked to food allergies

A new study using 5,000 stored blood samples found no increase in the presence of food-specific immunoglobulin E (IgE) — a blood marker associated with food allergy — in children's blood between the 1980s and the 2000s. [More]
Researchers observe worrisome increase in anaphylaxis rate

Researchers observe worrisome increase in anaphylaxis rate

Anaphylaxis, known to be a sudden and potentially life-threatening allergic reaction, seems to be increasing among children, according to a new study led by a team at the Research Institute of the McGill University Health Centre. [More]
Vanderbilt's A.S.A.P sees increase in number of patients treated for alpha-gal syndrome

Vanderbilt's A.S.A.P sees increase in number of patients treated for alpha-gal syndrome

Vanderbilt's Asthma, Sinus and Allergy Program (A.S.A.P) has seen an increase in the number of patients being treated for alpha-gal syndrome, commonly known as the red meat allergy linked to tick bites. [More]
Cinqair (reslizumab) approved for treatment of severe asthma

Cinqair (reslizumab) approved for treatment of severe asthma

The U.S. Food and Drug Administration today approved Cinqair (reslizumab) for use with other asthma medicines for the maintenance treatment of severe asthma in patients aged 18 years and older. Cinqair is approved for patients who have a history of severe asthma attacks (exacerbations) despite receiving their current asthma medicines. [More]
Anthim (obiltoxaximab) injection approved for treatment of inhalational anthrax

Anthim (obiltoxaximab) injection approved for treatment of inhalational anthrax

On Friday, March 18, the U.S. Food and Drug Administration approved Anthim (obiltoxaximab) injection to treat inhalational anthrax in combination with appropriate antibacterial drugs. Anthim is also approved to prevent inhalational anthrax when alternative therapies are not available or not appropriate. [More]
Baxalta seeks FDA approval for ADYNOVATE to treat children with hemophilia A and for use in surgical settings

Baxalta seeks FDA approval for ADYNOVATE to treat children with hemophilia A and for use in surgical settings

Baxalta Incorporated, a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, announced today that it has submitted supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration seeking approval for the use of ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated] to treat children under the age of 12 with hemophilia A and for use in surgical settings. [More]
Romosozumab for postmenopausal women with osteoporosis meets co-primary endpoints in Phase 3 study

Romosozumab for postmenopausal women with osteoporosis meets co-primary endpoints in Phase 3 study

Amgen and UCB today announced top-line results from the Phase 3 placebo-controlled FRActure study in postmenopausal woMen with ostEoporosis (FRAME). [More]
Advertisement
Advertisement